INTRODUCTION
Hypertensive disorders complicate 5-10% of all pregnancies and together they form one member of deadly triad, along with hemorrhage & infection that contribute greatly to maternal morbidity and mortality rates. 1 Pregnancy induced hypertension includes a group of hypertensive disorders developed due to gravid state after 20 weeks of pregnancy. Preeclampsia may be mild or severe. HELLP (Hemolysis, Elevated liver enzymes, Low platelet counts) syndrome is a complication of severe preeclampsia/eclampsia. 2 Incidence of Eclampsia in the developed countries is about 1 in 2000 deliveries 3 as compared to developing countries [4] [5] [6] where it varies from 1 in 100 to 1 in 1700. Preeclampsia/eclampsia probably accounts for more than 50,000 maternal deaths worldwide each year.
Canadian Hypertension Society. The ISSHP classification is currently widely accepted and includes the following categories: (i) pre-Eclampsia; (ii) chronic hypertension (essential or secondary); (iii) pre-Eclampsia superimposed on chronic hypertension; and (iv) gestational hypertension.
Gestational hypertension
 Systolic B.P.≥140 or diastolic B.P.≥90mm Hg for the first time during pregnancy.  No proteinuria.  B.P. returns to normal before 12 weeks postpartum.  Final diagnosis made only postpartum.
Preeclampsia-minimum criteria  B.P.≥140/90 mm Hg after 20 weeks gestation  Proteinuria ≥300 mg/24 hrs or ≥1+ dipstick.
Increased certainty of preeclampsia  B.P. ≥160/110 mm Hg  Proteinuria ≥2g/24 hr or ≥2+ dipstick  Sr. creatinine >1.2 mg/dl unless known to be previously elevated.  Platelets <100000/μL  Microangiopathic hemolysis-increased LDH  Elevated AST or ALT.  Persistent headache or other cerebral or visual disturbance  Persistent epigastric pain.
Eclampsia Seizures that cannot be attributed to other cause in a women with preeclampsia.
Superimposed preeclampsia on chronic hypertension
 New onset proteinuria≥ 300mg/24 hr in hypertensive women but no proteinuria before 20 weeks gestation.
A sudden increase in proteinuria or B.P. or platelet count<100000/μL in women with hypertension and proteinuria before 20 weeks gestation.
Chronic hypertension  B.P.≥ 140/90 mm Hg before pregnancy or diagnose before 20 weeks gestation not attributable to gestational trophoblastic disease. Or  Hypertension first diagnosed after 20 weeks and persistent after 12 weeks postpartum.
The present study was carried out with the following aims and objectives: 
METHODS
Maharaja Yashwantrao Hospital, Indore is a referral centre which provides level III care to its patients. This study was carried out in the Department of Obstetrics & Gynaecology of this institution in which Labetalol, Nifedipine and Methyldopa will be administered to the patients with pregnancy induced hypertension as a mode of conservative management to improve fetal maturity thereby increasing chances of fetal viability. The study will be carried out over a period of 12 months from October 2010to September 2011. A total 50 patients in each group will be included in the study.
Study design
The trial will be conducted as a comparative prospective randomized case study. The controls will not be taken as on ethical grounds it will not be possible to give placebo therapy to patients with severe hypertension in pregnancy.
Inclusion criteria
 All patients with hypertension whose two blood pressure recordings are >140/90 mm Hg more than 6 hours apart.  Patients with severe hypertension (Systolic blood pressure >169 mm Hg or Diastolic blood pressure >110 mm Hg) will be included in the study.  Patients with gestational age from 27 weeks up to 36 weeks will be included in the trial.  Patients who are sure of their LMP with regular cycles or those with first trimester ultrasound will be taken in the study.
Exclusion criteria
 Patients with severe preeclampsia (Systolic blood pressure >160 mm Hg or Diastolic blood pressure >110 mm Hg), with albuminuria of more than 2+ will be excluded from the study. Edema of face and hands will be considered more significant as compared to ankle edema.  Patients receiving more than one antihypertensive drug since admission will be excluded from study.  Patients with IUD since admission.
Inpatients will be monitored daily for blood pressure, urine albumin, FHS and mean arterial pressure.
Patients will be monitored with routine investigations, fundus examinations, renal profile and coagulation profile. Ultrasonography with colour Doppler will be done at the time of admission and repeated as required.
Aim of antihypertensive therapy in the management of PIH is to prevent complications due to hypertension while prolonging the course of pregnancy. It is generally indicated that severe hypertension require antihypertensive therapy. But in mild and moderate hypertension the need for antihypertensive therapy is to prevent progression to severe hypertension. The commonly used antihypertensive drugs in pregnancy are nifedipine, methyldopa, labetalol and hydralazine. 8 Labetalol will be started with an initial dose of 100 mg BD and the dose will be increased as required. The maximum dose of 100 mg TDS will be given. Nifedipine will be started with an initial dose of 10 mg BD and the dose will be increased upto 20 mg TDS. Methyldopa will be given in a dose of 250 mg BD and/or a max of 500 mg TDS.
All patients with live fetus at entry will be included. Conservative treatment will be attempted to attain fetal lung maturity and to avoid maternal complications. Therapy will be abandoned if maternal or fetal complications occur.
The treatment in any of the drugs will not be prolonged beyond 37 completed weeks.
After labor, the placenta was inspected, weighed, and any infarcts, calcifications or anomalies will be noted.
The mother as well as the baby will be followed up for a period of at least one week.
The gestational age at delivery, birth weight, sex, Apgar score, and heart rate will be recorded as well as the need for admission to and the time spent in the special care nursery. The development of respiratory distress syndrome or jaundice will be noted. Blood glucose measurements of the neonates will be done if clinically indicated. The mother will be followed up till the duration her blood pressure comes to baseline level.
RESULTS
Total 150 patients were enrolled for this study. They were divided into three groups of 50 cases each. Groups are labelled asGroup A-Nifedipine Group B-Labetalol Group Cmethyldopa Maximum cases in all three groups belong to age of 21 to 25 years and most cases were primigravida. Since MYH is government hospital, most of patients from rural community and hence illiterate too. 
The patients who had preterm labour (<37 weeks) were compared in each group and the result was statistically insignificant in between three groups.
Incidences of severe hypertensive episodes were maximum in Methyldopa group. Incidence of placental abruption was nil in labetalol group. Incidences of eclampsias nill in nifedipine group as compared to 1 case in both other groups. The present study showed a lower incidence of preterm labour (28%) in Labetalol group as compared to Methyldopa group. In another study conducted by Sachdeva et al 10 the incidence of PIH was found to be higher in rural women, though the difference was not significant. In our study also majority of cases (58.6%) of PIH belong to rural population. Since our hospital is catering a larger rural population; other factors like poverty, unawareness, lack of ante-natal care seeking behaviour and poor availability of health care services in rural areas are also responsible for same. Our study showed that younger age of pregnant women (66.6%) might have contributed to a greater frequency of PIH. Another study conducted by Yadav et al 11 also concluded that the incidence of PIH is greater when the age of pregnant women was less than 25 years. Our study also concluded that primiparous (50.6%) are at more risk of developing PIH. Sibai and Cunningham reviewed a number of worldwide studies and concluded that the incidence of pre-eclampsia in nulliparous was more than that for multiparous. Our study concludes that all three antihypertensive drugs-nifedipine, labetalol and methyldopa are equally effective in controlling both systolic and diastolic blood pressure. Although the rate of decreasing urine albumin is highest among the patients giving labetalol. Episode of severe hypertensive crisis was reported in 8% of cases receiving methyldopa; may be due to slow onset of action. Incidence of LSCS were maximum (28%) in group of nifedipine. Since it is calcium channel blocker, this mode of action may contribute to this side effect. No statistically difference is noted among the groups regarding the foetal and perinatal outcome.
CONCLUSION
All three drugs are safe & effective drug in treatment of PIH. Labetalol is more effective in reducing albuminuria as compared to nifedipine & methyldopa.
